首页 > 产品目录 > 免疫学 > 抗体 > Anti-CDKN2A/p14ARF antibody [ARF 4C6/4]

Anti-CDKN2A/p14ARF antibody [ARF 4C6/4]

产品编号 :
英文名称 :
中文名称 :
产品等级 :
品牌 :
包装规格 交货周期 质量标准 目录价 会员专享价 数量
100ug
- +
产品详情
  • 产品名称

    Anti-CDKN2A/p14ARF抗体[ARF 4C6/4]
    参阅全部 CDKN2A/p14ARF 一抗

  • 描述

    小鼠单克隆抗体[ARF 4C6/4] to CDKN2A/p14ARF

  • 宿主

    Mouse

  • 经测试应用

    适用于: Flow CytICC/IFmore details

  • 种属反应性

    与反应: Human

  • 免疫原

    Tissue, cells or virus corresponding to Bacteria CDKN2A/p14ARF.

  • 常规说明


    The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.

    If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As

  • 形式

    Liquid

  • 存放说明

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

  • 存储溶液

    Preservative: 0.02% Sodium azide
    Constituent: 99.98% PBS

  • 浓度

    • 100 µg 浓度为 1 mg/ml

    • 100 µg 浓度为 1 mg/ml

  • 纯度

    Protein A purified

  • 克隆

    单克隆

  • 克隆编号

    ARF 4C6/4

  • 骨髓瘤

    Sp2/0-Ag14

  • 同种型

    IgG2a

The Abpromise guarantee

Abpromise™承诺保证使用ab11048于以下的经测试应用

“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。

应用Ab评论说明
Flow Cyt

Use 0.5µg for 106 cells. 

ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody. 

ICC/IF

Use at an assay dependent concentration.

  • 数据库链接

  • 别名

    • CDKN2 antibody

    • CDKN2A antibody

    • Cell cycle negative regulator beta antibody

    • CMM2 antibody

    • Cyclin dependent kinase 4 inhibitor A antibody

    • Cyclin dependent kinase inhibitor 2A antibody

    • INK4 antibody

    • INK4a antibody

    • Melanoma p16 inhibits CDK4 antibody

    • MLM antibody

    • MTS 1 antibody

    • MTS1 antibody

    • Multiple tumor suppressor 1 antibody

    • p14 antibody

    • p16 antibody

    • p16 INK4a antibody

    • p16INK4a antibody

    • p19 antibody

    • P19ARF antibody

    • TP16 antibody

    • ARF antibody

    • CDK4 inhibitor p16 INK4 antibody

    • CDK4I antibody

  • Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p14ARF antibody [ARF 4C6/4] (ab11048)

    Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p14ARF antibody [ARF 4C6/4] (ab11048)

    ICC/IF image of ab11048 stained human MCF7 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1% BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab11048, 1 µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue). This antibody also gave a positive IF result in HeLa, Hek293 and HepG2cells.

  • Flow Cytometry - Anti-CDKN2A/p14ARF antibody [ARF 4C6/4] (ab11048)

    Flow Cytometry - Anti-CDKN2A/p14ARF antibody [ARF 4C6/4] (ab11048)

    Overlay histogram showing HeLa cells stained with ab11048 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab11048, 0.5µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG2a [ICIGG2A] (ab91361, 1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.